"Gastro intestinal cancer" trang 1 - tải miễn phí từ tailieunhanh
Relevance of internal time and circadian robustness for cancer patients

Relevance of internal time and circadian robustness for cancer patients
12    68    1
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: A single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: A single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
10    4    1
Incidence and time trends of sarcoma (2000–2013): Results from the French network of cancer registries (FRANCIM)

Incidence and time trends of sarcoma (2000–2013): Results from the French network of cancer registries (FRANCIM)
11    71    0
Vulnerability in elderly patients with gastrointestinal cancer – translation, cultural adaptation and validation of the European Portuguese version of the Vulnerable Elders Survey (VES-13)

Vulnerability in elderly patients with gastrointestinal cancer – translation, cultural adaptation and validation of the European Portuguese version of the Vulnerable Elders Survey (VES-13)
10    56    1
Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development
10    35    1
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
14    65    1
The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers

The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers
9    36    1
Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT

Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT
4    45    1
The off-label use of targeted therapies in sarcomas: The OUTC’S program

The off-label use of targeted therapies in sarcomas: The OUTC’S program
11    45    1